Why Healthcare’s Frontline Challenges Expose the Limits of Traditional HR Practices
Workforce analyst Nehal Nangia shows how a redesign of work, scheduling, and career pathways is needed to tackle the growing worker crisis Healthcare systems face…
Articles by Matthew Driver
Why HealthTech Should Receive the Same “Automatic” Treatment in Funding and Uptake as Medicines
In April, MHRA and NICE announced a new joint pathway to expedite patient access to medicines by streamlining licensing and value assessment. This pathway synchronises…
The First Mile: Healthcare’s Fulfilment Control Tower
In healthcare, supply chains for pharmaceuticals and medtech have long been judged by their performance at the point of delivery. But as the industry deals…
Agentis Health Group Acquires Clinical Pharmacist Solutions to Strengthen Digital Healthcare Business
UK-based pharmacy and digital health management specialist looks to boost presence in primary care and long-term condition management, in alignment with the goals of the…
Dylan Roberts Joins the Highland Advisory Board
Digital leader with a wealth of local government and health experience becomes a member of the panel of IT professionals and industry experts that supports…
What Online Reviews Can and Cannot Tell You About Care
Most people now begin a healthcare decision the same way they begin a hotel booking. They search a name, scan the stars, and read a…
The Hidden Fulfilment Complexity Behind Private Prescriptions in UK Clinics
Private prescribing is often discussed at the point of clinical decision-making. Yet for many UK clinics, the operational complexity begins immediately after the prescription is…
Trust, not Accuracy, is the Real Bottleneck in AI-enabled Patient Safety
AI-driven pharmacovigilance has spent the past two years chasing model accuracy, on the assumption that better performance would translate directly into lighter workloads. Jason Bryant,…
Regulatory Trends in AI-enabled SaMDs
FDA authorisations of AI-enabled software as medical devices (SaMDs) have increased significantly. Over 50% of FDA authorisations have occurred since 2022 with the majority (76%)…
GLP-1s’ Challenge to Pharmacovigilance
The international popularity of GLP-1 agonists for weight loss has presented an unforeseen operational challenge for pharma as companies try to keep track of emerging…